US equities
|
MU
$986.93
▼-4.09%
META
$742.86
▲+3.37%
NVDA
$226.29
▼-1.30%
SNDK
$1,476.15
▼-6.68%
SPCX
$164.08
▲+0.93%
AMD
$589.87
▼-3.00%
MSFT
$539.80
▲+0.88%
TSLA
$378.48
▼-1.10%
MU
$986.93
▼-4.09%
META
$742.86
▲+3.37%
NVDA
$226.29
▼-1.30%
SNDK
$1,476.15
▼-6.68%
SPCX
$164.08
▲+0.93%
AMD
$589.87
▼-3.00%
MSFT
$539.80
▲+0.88%
TSLA
$378.48
▼-1.10%
FinancialContent
Sign in
Markets
Overview
News
World markets
Treasuries
Currencies
Commodities
Economy
Stocks
Overview
Most active
Gainers
Losers
Largest companies
52-week gainers
52-week losers
ETFs
Overview
Popular funds
Most active
Gainers
Losers
News
Research
Search
Sectors
Ultragenyx Pharmaceutical Inc. - Common Stock
(NQ:
RARE
)
15.12
-0.36 (-2.33%)
Delayed Quote
Updated: 3:09 PM EDT, Oct 12, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Ultragenyx Pharmaceutical Inc. - Common Stock
< Previous
1
2
3
4
5
6
7
8
9
...
17
18
Next >
Ultragenyx Shareholder Alert: ClaimsFiler Reminds Investors With Losses In Excess Of $100,000 Of Lead Plaintiff Deadline In Class Action Lawsuit Against Ultragenyx Pharmaceutical Inc. - RARE
March 18, 2026
From
SkyMedia, LLC
Via
GlobeNewswire
RARE CLASS ACTION NOTICE: Faruqi & Faruqi, LLP Reminds Ultragenyx Pharmaceutical (RARE) Investors of Securities Class Action Deadline on April 6, 2026
March 18, 2026
From
Faruqi & Faruqi LLP
Via
GlobeNewswire
Ultragenyx Pharmaceutical Inc. Notice of April 6, 2026 Application Deadline for Class Action Lawsuit - Contact Lewis Kahn, Esq. at Kahn Swick & Foti, LLC, Before Application Deadline
March 17, 2026
From
Kahn Swick & Foti, LLC
Via
GlobeNewswire
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Ultragenyx Pharmaceutical Inc. of Class Action Lawsuit and Upcoming Deadlines – RARE
March 17, 2026
From
Pomerantz LLP
Via
GlobeNewswire
RARE Investors Have Opportunity to Lead Ultragenyx Pharmaceutical Inc. Securities Fraud Lawsuit with the Schall Law Firm
March 16, 2026
From
Schall Law
Via
GlobeNewswire
RARE UPCOMING DEADLINE: Faruqi & Faruqi, LLP Reminds Ultragenyx Pharmaceutical (RARE) Investors of Securities Class Action Deadline on April 6, 2026
March 14, 2026
From
Faruqi & Faruqi LLP
Via
GlobeNewswire
RARE Investors Have Opportunity to Lead Ultragenyx Pharmaceutical Inc. Securities Fraud Lawsuit with the Schall Law Firm
March 13, 2026
From
Schall Law
Via
GlobeNewswire
RARE DEADLINE ALERT: Faruqi & Faruqi, LLP Reminds Ultragenyx Pharmaceutical (RARE) Investors of Securities Class Action Deadline on April 6, 2026
March 13, 2026
From
Faruqi & Faruqi LLP
Via
GlobeNewswire
ROSEN, A LEADING LAW FIRM, Encourages Ultragenyx Pharmaceutical Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - RARE
March 12, 2026
From
The Rosen Law Firm PA
Via
GlobeNewswire
Ultragenyx Announces Positive 36-Week Data from Phase 3 Study of DTX301 AAV8 Gene Therapy for the Treatment of Ornithine Transcarbamylase (OTC) Deficiency
March 12, 2026
From
Ultragenyx Pharmaceutical Inc.
Via
GlobeNewswire
Ultragenyx Shareholder Alert: ClaimsFiler Reminds Investors With Losses In Excess Of $100,000 Of Lead Plaintiff Deadline In Class Action Lawsuit Against Ultragenyx Pharmaceutical Inc. - RARE
March 11, 2026
From
SkyMedia, LLC
Via
GlobeNewswire
Ultragenyx Pharmaceutical Inc. Notice of April 6, 2026 Application Deadline for Class Action Lawsuit - Contact Lewis Kahn, Esq. at Kahn Swick & Foti, LLC, Before Application Deadline
March 10, 2026
From
Kahn Swick & Foti, LLC
Via
GlobeNewswire
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Ultragenyx Pharmaceutical Inc. of Class Action Lawsuit and Upcoming Deadlines – RARE
March 10, 2026
From
Pomerantz LLP
Via
GlobeNewswire
RARE Investors Have Opportunity to Lead Ultragenyx Pharmaceutical Inc. Securities Fraud Lawsuit with the Schall Law Firm
March 10, 2026
From
Schall Law
Via
GlobeNewswire
Ultragenyx Pharmaceutical Inc. (RARE) Class Action Lawsuit Seeks Recovery for Investors; April 6, 2026, Deadline - Contact Kessler Topaz Meltzer & Check, LLP
March 09, 2026
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
Via
NewMediaWire
Topics
Fraud
Lawsuit
Ultragenyx Pharmaceutical Inc. (RARE) Class Action Lawsuit Seeks Recovery for Investors; April 6, 2026, Deadline - Contact Kessler Topaz Meltzer & Check, LLP
March 09, 2026
Did you buy RARE common stock between August 3, 2023, and December 26, 2025?
Via
TheNewswire.com
Topics
Fraud
Lawsuit
CLASS ACTION INVESTOR ALERTS: Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Ultragenyx and Mereo BioPharma and Encourages Investors to Contact the Firm
March 08, 2026
From
Bragar Eagel & Squire
Via
GlobeNewswire
Ultragenyx Pharmaceutical Inc. (RARE) Investors Have Opportunity to Lead Securities Fraud Class Action Lawsuit
March 06, 2026
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
Via
NewMediaWire
Topics
Fraud
Lawsuit
Ultragenyx Pharmaceutical Inc. (RARE) Investors Have Opportunity to Lead Securities Fraud Class Action Lawsuit
March 06, 2026
Did you buy RARE common stock between August 3, 2023, and December 26, 2025?
Via
TheNewswire.com
Topics
Fraud
Lawsuit
RARE Investors Have Opportunity to Lead Ultragenyx Pharmaceutical Inc. Securities Fraud Lawsuit with the Schall Law Firm
March 06, 2026
From
Schall Law
Via
GlobeNewswire
Ultragenyx Pharmaceutical Inc. (RARE) Securities Fraud Class Action Lawsuit Filed; April 6, 2026, Lead Plaintiff Deadline
March 05, 2026
Did you buy RARE common stock between August 3, 2023, and December 26, 2025?
Via
TheNewswire.com
Topics
Fraud
Lawsuit
Ultragenyx Pharmaceutical Inc. (RARE) Securities Fraud Class Action Lawsuit Filed; April 6, 2026, Lead Plaintiff Deadline
March 05, 2026
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
Via
NewMediaWire
Topics
Fraud
Lawsuit
Ultragenyx Shareholder Alert: ClaimsFiler Reminds Investors With Losses In Excess Of $100,000 Of Lead Plaintiff Deadline In Class Action Lawsuit Against Ultragenyx Pharmaceutical Inc. - RARE
March 04, 2026
From
SkyMedia, LLC
Via
GlobeNewswire
Ultragenyx Pharmaceutical Inc. (RARE) Class Action Lawsuit: Investors Face April 6, 2026, Deadline
March 04, 2026
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
Via
NewMediaWire
Topics
Fraud
Lawsuit
Ultragenyx Pharmaceutical Inc. (RARE) Class Action Lawsuit: Investors Face April 6, 2026, Deadline
March 04, 2026
Did you buy RARE common stock between August 3, 2023, and December 26, 2025?
Via
TheNewswire.com
Topics
Fraud
Lawsuit
UPCOMING DEADLINE: Ultragenyx Pharmaceutical Inc. (RARE) Securities Fraud Class Action – April 6, 2026 Lead Plaintiff Deadline - Furuqi & Furuqi LLP
March 04, 2026
From
Faruqi & Faruqi LLP
Via
GlobeNewswire
Ultragenyx Pharmaceutical Inc. Notice of April 6, 2026 Application Deadline for Class Action Lawsuit - Contact Lewis Kahn, Esq. at Kahn Swick & Foti, LLC, Before Application Deadline
March 03, 2026
From
Kahn Swick & Foti, LLC
Via
GlobeNewswire
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Ultragenyx Pharmaceutical Inc. of Class Action Lawsuit and Upcoming Deadlines – RARE
March 03, 2026
From
Pomerantz LLP
Via
GlobeNewswire
RARE Investors Have Opportunity to Lead Ultragenyx Pharmaceutical Inc. Securities Fraud Lawsuit with the Schall Law Firm
March 03, 2026
From
Schall Law
Via
GlobeNewswire
NASDAQ: RARE INVESTOR ALERT: Berger Montague Advises Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) Investors of an April 6, 2026 Deadline
March 02, 2026
From
Berger Montague
Via
GlobeNewswire
< Previous
1
2
3
4
5
6
7
8
9
...
17
18
Next >
